Assignee
G1 THERAPEUTICS INC
US·57 granted patents·29 pending applications·897 citations·filing 2013–2023
Top patents by PatentIndex Score
86 records- 0199US10189850B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·17 cites·1 claims
- 0299US10189849B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·18 cites·1 claims
- 0399US10189851B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·19 cites·1 claims
- 0499US9499564B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 22, 2016·34 cites·2 claims
- 0599US9481691B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 1, 2016·31 cites·2 claims
- 0699US9102682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Aug 11, 2015·42 cites·16 claims
- 0799US8829012B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 9, 2014·47 cites·47 claims
- 0899US8822683B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 2, 2014·55 cites·37 claims
- 0999US8691830B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Apr 8, 2014·53 cites·42 claims
- 1099US8598197B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·65 cites·58 claims
- 1199US8598186B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·81 cites·24 claims
- 1298US11040042B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·5 cites·2 claims
- 1398US10927120B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·3 claims
- 1498US10085992B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Oct 2, 2018·16 cites·9 claims
- 1598US10076523B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2016·Granted Sep 18, 2018·15 cites·15 claims
- 1698US9957276B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·14 cites·57 claims
- 1798US9931345B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·14 cites·20 claims
- 1898US9527857B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2014·Granted Dec 27, 2016·31 cites·74 claims
- 1998US9487530B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Nov 8, 2016·36 cites·50 claims
- 2098US9464092B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Oct 11, 2016·29 cites·54 claims
- 2197US11717523B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·3 cites·21 claims
- 2297US11654148B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2021·Granted May 23, 2023·4 cites·16 claims
- 2397US10696682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jun 30, 2020·6 cites·12 claims
- 2497US10434104B2HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·7 cites·10 claims
- 2597US9260442B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Feb 16, 2016·42 cites·14 claims
- 2696US10925878B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Feb 23, 2021·5 cites·85 claims
- 2796US10709711B2Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·6 cites·8 claims
- 2896US10660896B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·5 cites·21 claims
- 2996US9717735B2Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2015·Granted Aug 1, 2017·16 cites·60 claims
- 3095US12168666B2Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2021·Granted Dec 17, 2024·8 cites·27 claims
- 3195US11090306B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2019·Granted Aug 17, 2021·9 cites·6 claims
- 3295US10988479B1Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2020·Granted Apr 27, 2021·15 cites·14 claims
- 3395US10981887B2Benzothiophene estrogen receptor modulatorsG1 THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·3 cites·19 claims
- 3495US10966984B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·5 cites·30 claims
- 3595US10413547B2Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·11 cites·3 claims
- 3695US9745316B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Aug 29, 2017·14 cites·20 claims
- 3794US12285431B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2021·Granted Apr 29, 2025·2 cites·9 claims
- 3894US12139494B2Morphic forms of G1T38 and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2022·Granted Nov 12, 2024·3 cites·1 claims
- 3994US11708337B2Synthesis of 1,4-diazaspiro[5.5]undecan-3-oneG1 THERAPEUTICS INC·Filed 2021·Granted Jul 25, 2023·5 cites·26 claims
- 4094US11357779B2G1T38 superior dosage regimesG1 THERAPEUTICS INC·Filed 2020·Granted Jun 14, 2022·7 cites·52 claims
- 4193US11395821B2Treatment of EGFR-driven cancer with fewer side effectsG1 THERAPEUTICS INC·Filed 2019·Granted Jul 26, 2022·9 cites·7 claims
- 4293US11261193B2Morphic forms of G1T38 and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·5 cites·20 claims
- 4392US10865210B2Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-aminesG1 THERAPEUTICS INC·Filed 2018·Granted Dec 15, 2020·9 cites·37 claims
- 4492US10376519B2Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2017·Granted Aug 13, 2019·5 cites·10 claims
- 4592US10231969B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumorsG1 THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·12 cites·13 claims
- 4692US9856268B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted Jan 2, 2018·9 cites·20 claims
- 4791US11629150B2Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-aminesG1 THERAPEUTICS INC·Filed 2020·Granted Apr 18, 2023·3 cites·5 claims
- 4891US11446295B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumorsG1 THERAPEUTICS INC·Filed 2019·Granted Sep 20, 2022·4 cites·6 claims
- 4991US10654831B2Antiproliferative pyrimidine-based compoundsG1 THERAPEUTICS INC·Filed 2018·Granted May 19, 2020·5 cites·19 claims
- 5090US10829490B2Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·5 cites·29 claims
Showing the top 50 of 86 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →